Prima BioMed Announces First Safety, Pharmacokinetics and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Prima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321

SYDNEY, AUSTRALIA--(Marketwired - Jun 21, 2016) - Prima BioMed Ltd ( ASX : PRR ) ( NASDAQ : PBMD ), a leading immuno-oncology company, is pleased to announce initial safety data from the first cohort of patients in its Phase IIb AIPAC chemo-immunotherapy clinical study of Prima's lead compound, IMP321.

AIPAC ( A ctive I mmunotherapy PAC litaxel) is a multi-national, randomised, double-blind, placebo-controlled study of IMP321-plus-paclitaxel in hormone receptor-positive metastatic breast cancer. The trial is currently being conducted out of Belgium, The Netherlands and now also Hungary, with further European sites to be initiated in the future.

The first six patients have received 6 mg doses of IMP321 in combination with paclitaxel. This dose has proved to be safe and well tolerated with no drug related serious adverse events. The data also demonstrated activation of blood monocytes/dendritic cells and CD8 T cells.

Prima's Chief Medical Officer, Dr Frederic Triebel, said: "The data from this initial open-label run-in cohort of six patients confirms the safety, pharmacokinetics and pharmacodynamics of IMP321 and we are encouraged to have met our anticipated timelines for recruitment. We will now start enrolling nine additional patients in the second cohort with 30 mg of IMP321, with the results of both cohorts to be presented and compared in the fourth quarter of 2016. Then the randomisation phase with the recommended phase IIb dose will begin enrolling approximately 196 patients." 

Prima's CEO, Marc Voigt, commented: "We are pleased to have confirmed previous results at the 6 mg dose in metastatic breast cancer. We believe that the interim results obtained at 6 mg significantly de-risk the remainder of the trial as the previous phase I/IIa trials provided very encouraging results with that dose level."

The primary purpose of the AIPAC trial is to determine the clinical benefit of IMP321 in terms of Progression-Free Survival as the primary clinical endpoint. Details of the AIPAC study are available at NCT 02614833 .

About IMP321

IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.

IMP321 has been shown in an open-label Phase I study 1 , to be able to double the expected six-month response rate in HER-2 negative metastatic breast cancer patients receiving standard-of-care paclitaxel; from a 25% historic response rate 2 (RECIST criteria), to 50% when combined with IMP321.

About Prima BioMed

Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au .

1 See Brignone et.al., J. Transl. Med. 2010, 8:71. 2  Miller et. al., N. Engl. J. Med. 2007, 357: 2666-76.

For further information please contact: Prima BioMed Ltd: Australia Investor/Media: Mr Matthew Gregorowski Citadel-MAGNUS +61 (2) 8234 0100 mgregorowski@citadelmagnus.com U.S. Investors: Matthew Beck The Trout Group LLC +1 (646) 378-2933 mbeck@troutgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 28

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 25

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 64

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 192

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 31

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 328

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 195

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 13

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 16

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading

Top 5 Most Recently Viewed Articles

GM Partners with Barclays to Enhance Credit Card Offerings

Updated Category News Views 71

General Motors and Barclays Sign a Strategic Partnership General Motors (NYSE: GM) and Barclays have recently announced a significant long-term partnership that focuses on credit card services. This strategic agreement reflects both companies' commitment to enhancing customer experience and providing innovative financial solutions. Benefits of the New Credit Card...

Continue Reading
Enbridge Inc. Declares 3% Increase in Quarterly Dividend

Updated Category News Views 126

Enbridge Inc. Increases Quarterly Dividend by 3% Enbridge Inc. (TSX: ENB) has made a significant announcement regarding its quarterly dividend. The company declared a quarterly dividend of $0.9425 per common share, signaling a 3% increase from previous rates. This notable hike reflects Enbridge's commitment to shareholder value and marks the thirtieth consecutive year of...

Continue Reading
Jefferies Advises Caution on Biotech-Related CRO Investments

Updated Category News Views 545

CROs Confront Challenges as Biotech Market Slows In a recent analysis, Jefferies is advising investors to rethink their investments in contract research organizations (CROs), particularly those focused on biotech and early-stage research. This caution comes as the demand in the biotech sector has noticeably declined. Financial Struggles Affects Companies Jefferies has...

Continue Reading
Remarkable Cost Savings with QUELIMMUNE for Pediatric AKI

Updated Category News Views 137

Significant Economic Impact of QUELIMMUNE Therapy SeaStar Medical Holding Corporation (Nasdaq: ICU), a pioneering healthcare company, has recently published a health economic analysis that underscores the substantial financial benefits of its QUELIMMUNE therapy for pediatric patients suffering from Acute Kidney Injury (AKI). The analysis highlights an estimated average...

Continue Reading
SKF Invites Fans to Revitalize Tattoos with Brand Update

Updated Category News Views 228

SKF Invites Fans to Revitalize Tattoos with Brand Update SKF has taken an impactful step to modernize its brand identity, showcasing a fresh and dynamic look aimed at connecting with its audience more effectively. This update marks the company's first significant change to its logo since its inception in 1908, highlighting the dedication to innovation while respecting its...

Continue Reading